{
    "nctId": "NCT05770713",
    "briefTitle": "A Real-life Study to Learn About the Use and Effects of the CDK4/6 Inhibitors in Canadian Patients With Breast Cancer.",
    "officialTitle": "Treatment Patterns And Clinical Outcomes Among Patients Receiving CDK4/6 Inhibitors Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In A Canadian Real World Setting",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 48,
    "primaryOutcomeMeasure": "Number of Participants Classified According to Treatment Pattern",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* HR+/HER2- breast cancer diagnosis with confirmed metastatic or advanced disease\n* Diagnosed with ABC/MBC between 01 Jan 2016 and 01 July 2021\n* Treatment with CDK4/6 inhibitor\n\nExclusion Criteria:\n\n* Patient does not have ABC/MBC\n* Patient has indicated HR- or HER2+ status\n* Patient received a CDK4/6i as part of a clinical trial",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}